Anakinra is an antagonist of IL‐1 receptor, which inhibits IL‐1α and IL‐1β activities, and is approved by the FDA to be used to treat adult COVID-19 inpatients with positiveness of COVID-19 with pneumonia and requiring supplemental oxygen. The gene discussed is IL1B; the disease is COVID-19.